Maven Securities LTD acquired a new position in Sientra Inc (NASDAQ:SIEN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 300,000 shares of the medical instruments supplier’s stock, valued at approximately $1,815,000. Maven Securities LTD owned about 1.03% of Sientra as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Schroder Investment Management Group purchased a new position in shares of Sientra during the second quarter valued at approximately $7,700,000. AWM Investment Company Inc. purchased a new position in Sientra during the 2nd quarter worth $2,156,000. Monashee Investment Management LLC purchased a new position in Sientra during the 2nd quarter worth $1,602,000. Granite Point Capital Management L.P. boosted its holdings in Sientra by 15.3% during the 2nd quarter. Granite Point Capital Management L.P. now owns 1,014,898 shares of the medical instruments supplier’s stock worth $6,252,000 after acquiring an additional 134,898 shares during the last quarter. Finally, Stephens Inc. AR grew its stake in shares of Sientra by 81.1% in the 2nd quarter. Stephens Inc. AR now owns 254,832 shares of the medical instruments supplier’s stock worth $1,570,000 after acquiring an additional 114,132 shares in the last quarter. 88.96% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:SIEN traded up $0.03 during midday trading on Wednesday, reaching $7.11. The company had a trading volume of 45,780 shares, compared to its average volume of 756,854. The stock has a market cap of $326.31 million, a P/E ratio of -2.19 and a beta of 0.25. The company’s 50 day moving average price is $6.36 and its 200 day moving average price is $7.36. The company has a current ratio of 2.33, a quick ratio of 1.99 and a debt-to-equity ratio of 0.18. Sientra Inc has a 52-week low of $4.78 and a 52-week high of $25.77.

Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.50). Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The company had revenue of $20.53 million for the quarter, compared to analysts’ expectations of $19.04 million. During the same quarter last year, the business posted ($0.73) EPS. The business’s quarterly revenue was up 17.0% on a year-over-year basis. Research analysts forecast that Sientra Inc will post -2.35 EPS for the current fiscal year.

SIEN has been the subject of several analyst reports. Wells Fargo & Co upgraded shares of Sientra from a “market perform” rating to an “outperform” rating and increased their target price for the company from $8.00 to $10.00 in a report on Wednesday, June 5th. Maxim Group restated a “buy” rating and set a $12.00 price target (down from $16.00) on shares of Sientra in a report on Friday, August 9th. Canaccord Genuity upped their price objective on shares of Sientra from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Stephens set a $16.00 price objective on shares of Sientra and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Craig Hallum dropped their target price on shares of Sientra from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $15.75.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Further Reading: What are momentum indicators and what do they show?

Institutional Ownership by Quarter for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.